Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Department of Immunology, University of Toronto, Toronto, ON, Canada.
Leukemia. 2024 Oct;38(10):2210-2224. doi: 10.1038/s41375-024-02325-4. Epub 2024 Aug 8.
Despite selective HDAC3 inhibition showing promise in a subset of lymphomas with CREBBP mutations, wild-type tumors generally exhibit resistance. Here, using unbiased genome-wide CRISPR screening, we identify GNAS knockout (KO) as a sensitizer of resistant lymphoma cells to HDAC3 inhibition. Mechanistically, GNAS KO-induced sensitization is independent of the canonical G-protein activities but unexpectedly mediated by viral mimicry-related interferon (IFN) responses, characterized by TBK1 and IRF3 activation, double-stranded RNA formation, and transposable element (TE) expression. GNAS KO additionally synergizes with HDAC3 inhibition to enhance CD8 T cell-induced cytotoxicity. Moreover, we observe in human lymphoma patients that low GNAS expression is associated with high baseline TE expression and upregulated IFN signaling and shares common disrupted biological activities with GNAS KO in histone modification, mRNA processing, and transcriptional regulation. Collectively, our findings establish an unprecedented link between HDAC3 inhibition and viral mimicry in lymphoma. We suggest low GNAS expression as a potential biomarker that reflects viral mimicry priming for enhanced response to HDAC3 inhibition in the clinical treatment of lymphoma, especially the CREBBP wild-type cases.
尽管选择性 HDAC3 抑制在具有 CREBBP 突变的部分淋巴瘤中显示出前景,但野生型肿瘤通常表现出耐药性。在这里,我们使用无偏基因组范围的 CRISPR 筛选,鉴定出 GNAS 敲除(KO)是对 HDAC3 抑制有抗性的淋巴瘤细胞的敏化剂。从机制上讲,GNAS KO 诱导的敏化作用不依赖于经典 G 蛋白活性,但出乎意料的是通过病毒模拟相关干扰素(IFN)反应介导,其特征是 TBK1 和 IRF3 激活、双链 RNA 形成和转座元件(TE)表达。GNAS KO 还与 HDAC3 抑制协同作用,增强 CD8 T 细胞诱导的细胞毒性。此外,我们在人类淋巴瘤患者中观察到,低 GNAS 表达与高基线 TE 表达和上调的 IFN 信号相关,并且与 GNAS KO 在组蛋白修饰、mRNA 处理和转录调控方面具有共同的破坏生物学活性。总之,我们的发现在淋巴瘤中建立了 HDAC3 抑制与病毒模拟之间前所未有的联系。我们建议低 GNAS 表达作为一个潜在的生物标志物,反映了病毒模拟的启动,以增强对 HDAC3 抑制的反应,在淋巴瘤的临床治疗中,特别是 CREBBP 野生型病例。